• Explore /
  • Poster
  • / Randomized phase I/II trial of TheraT vectors expressing HPV16 specific antigens with neoadjuvant chemotherapy followed by transoral robotic surgery (TORS) or risk/response stratified chemoradiotherapy (CRT) for locoregional HPV16+ oropharyngeal cancer (OPC).

Randomized phase I/II trial of TheraT vectors expressing HPV16 specific antigens with neoadjuvant chemotherapy followed by transoral robotic surgery (TORS) or risk/response stratified chemoradiotherapy (CRT) for locoregional HPV16+ oropharyngeal cancer (OPC).

Abstract Poster

Authors

null

Ari Rosenberg

Department of Medicine, University of Chicago, Chicago, IL

Ari Rosenberg , Nishant Agrawal , Aditya Juloori , Theodore Karrison , Jeffrey Chin , Rifat Hasina , Zhen Gooi , Elizabeth A. Blair , Daniel J. Haraf , Evgeny Izumchenko , Alexander T. Pearson , Everett E. Vokes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Local-Regional Disease

Clinical Trial Registration Number

NCT05108870

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS6115)

DOI

10.1200/JCO.2023.41.16_suppl.TPS6115

Abstract #

TPS6115

Poster Bd #

100a

Abstract Disclosures

Similar Posters

First Author: Marshall R. Posner

First Author: Krzysztof Misiukiewicz

First Author: Marshall R. Posner

First Author: Ari Rosenberg